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Abstract. Localization of prostate cancer recurrence, 
particularly in the bones, is a major challenge with standard 
of care imaging in patients with biochemical recurrence 
following curatively intended treatment. Gallium-68-labeled 
prostate specific membrane antigen positron emission tomog-
raphy/computed tomography (68Ga-PSMA PET/CT) is a 
novel and promising method for imaging in prostate cancer. 
The present study reports two cases of patients with prostate 
cancer with biochemical recurrence, with evidence of bone 
metastases on 68Ga-PSMA PET/CT images and low prostate 
specific antigen PSA levels (<2 ng/ml) and PSA doubling time 
>6 months. The bone metastases were verified by supplemen-
tary imaging with 18F‑sodium fluoride PET/CT and magnetic 
resonance imaging as well as biochemical responses to 
androgen deprivation therapy. Therefore, 68Ga-PSMA PET/CT 
is promising for the restaging of patients with prostate cancer 
with biochemical recurrence, including patients with low PSA 
levels and low PSA kinetics.
Introduction
Localization of prostate cancer recurrence is a major challenge 
in patients with biochemical recurrence following curatively 
intended treatment. The currently applied imaging modalities 
such as bone scintigraphy and abdominal pelvic computed 
tomography (CT) are too insensitive, particularly at low 
serum prostate‑specific antigen (PSA) values (1). These two 
modalities only reliably show the site of relapse in patients 
with very high PSA levels (>10 ng/ml) (2). This is of particular 
importance as salvage radiotherapy in these patients is most 
effective at serum PSA values <0.5 ng/ml (3,4).
Established positron emission tomography (PET) tracers 
such as 11C- or 18F-choline or 11C-acetate are able to directly 
detect tumor tissue, which is also true at the bone level, where 
these tracers show tumor tissue, as opposed to reactive bone 
as with bone scans and 18F‑sodium fluoride (NaF) PET/CT. 
This result may convey higher sensitivity for both osteoblastic 
and osteolytic bone lesions at low PSA levels (5). However, 
the majority of large series have included patients with a PSA 
level >2 ng/ml (6,7). Most studies that included patients with 
low PSA levels have shown infrequent bone metastases, and 
little information is provided concerning tumor characteristics 
in individual patients (8-11). Generally, choline PET is only 
indicated in biochemical failure if the PSA level is >2 ng/ml or 
the PSA level is rising rapidly (12).
Gallium‑68‑labelled prostate‑specific membrane antigen 
(68Ga-PSMA) PET/CT has recently been introduced as a 
promising method for prostate cancer imaging, both for 
staging and restaging (13-17). In contrast to existing PET 
tracers, 68Ga-PSMA PET has revealed pathological sites of 
uptake, even with low PSA levels, in several retrospective 
series (13-17).
In 2015, the present authors initiated two prospective 
trials with 68Ga-PSMA PET/CT in prostate cancer, including 
a study of PSMA-11 (DKFZ-PSMA-11, also known as 
PSMA-HBED-CC) PET/CT in recurrent prostate cancer in 
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comparison with magnetic resonance imaging (MRI) and 
NaF PET/CT (EudraCT no.; 2014‑005073‑37). The trial was 
approved by the Danish Health and Medicine Authority, The 
Danish Data Protection Agency, and the North Denmark 
Region Committee in Health Research Ethics. The patients 
received written and oral information and provided written 
informed consent, inclusive presentation of individual study 
results in a blinded fashion. The current study reports two 
cases of bone metastasis in patients with PSA levels <2 ng/ml 
and slow PSA kinetics.
Case reports
Case one. A 70-year old male was included in the present study 
in October 2015 due to biochemical recurrence of a prostate 
cancer. Five years previously, the patient underwent radical 
prostatectomy due to prostate cancer (T2c, Gleason 7 (3+4), 
with a PSA level of 10.9 ng/ml). The PSA values remained 
unmeasurable (<0.1 ng/ml) for 4 years but then increased to 
0.4 ng/ml. The PSA doubling time (PSAdt) was 22.5 months. 
A 68Ga-PSMA-11 PET/CT scan with low-dose CT showed 
pathological PSMA uptake in several bone lesions, with corre-
sponding morphological findings in the CT scan, including the 
right and left scapula, right 5th rib and left 3rd rib (Fig. 1). There 
was no pathological uptake in the lymph nodes, prostatic bed or 
soft tissues. In addition, the patient underwent an NaF PET/CT 
scan, which confirmed the skeletal findings on the 68Ga-PSMA 
PET/CT, but also revealed at least four additional bone metas-
tases (ribs and the left iliac bone), but without corresponding 
changes on the CT. The NaF PET/CT scan identified numerous 
sites of enhanced uptake associated with benign, degenerative 
bone disorders. The MRI scan did not identify any enlarged 
lymph nodes in the pelvis. A slightly heterogeneous bone 
marrow signal was observed in the pelvis and lumbar spine on 
T1-weighted images but without the anatomical appearance of 
bone metastases, and a normal signal on the short TI-inversion 
recovery (STIR) sequences. In conclusion, the MRI was nega-
tive for bone metastases. Notably, the MRI covered the pelvis 
and spine only as recommended by the European Society of 
Urological Oncology guideline for nodes and bone (18). Thus, 
the MRI was not able to confirm the four skeletal lesions. The 
patient received leuprorelin acetate and six cycles of docetaxel. 
The PSA level dropped to an unmeasurable level (nadir PSA 
level <0.1 ng/ml).
Case two. A 71-year old male was diagnosed with prostate 
cancer (pT2b, Gleason 7, with a PSA level of 16.1 ng/ml) in 2002. 
The patient received a radical prostatectomy with postoperative 
normalization of PSA levels (PSA level <0.1 ng/ml). Due to 
biochemical recurrence (a peak PSA level of 0.6 ng/ml) in 2006, 
the patient received salvage radiotherapy in 5 fields with a central 
dose of 48 Gray (34 fractions) supplemented with 12 months of 
treatment with flutamide. The PSA levels normalized within the 
first year following radiotherapy. In October 2014, the patient 
presented with an elevated PSA level (0.4 ng/ml) that further 
increased to 1.8 ng/ml at the time of evaluation in August 
2016 (PSAdt 8.7 months). A 68Ga-PSMA-11 PET/CT scan with 
low-dose CT revealed PSMA uptake in four small lymph nodes 
on the left side of the pelvis and a skeletal lesion at the level of 
fourth lumbar vertebra (Fig. 2). Low-dose CT showed a discrete 
sclerotic lesion at L4. There was no pathological PSMA uptake 
in other sites. The NaF PET/CT confirmed the lesion at L4 as 
a bone metastasis. There were no additional malignant bone 
lesions identified. The MRI found that the four lymph nodes 
detected on 68Ga-PSMA PET/CT were of normal size. The 
skeletal lesion was suspicious for malignancy on the MRI scan 
due to a low signal in the T1 image and high signal on the STIR 
sequence. However, a slight depression of the upper discus at 
L4 caused the final MRI‑based diagnosis to be equivocal for 
bone metastasis. The patient subsequently received treatment 
with bicalutamide, which caused the PSA level to decline to an 
unmeasurable level (<0.1 ng/ml).
Discussion
Imaging in cases of biochemical recurrence of prostate cancer 
has been hampered by the lack of appropriately sensitive 
modalities, particularly for bone lesions. Bone scans and CT 
in general do not have adequate sensitivity, and choline PET 
is only indicated if the PSA level is >2 ng/ml or if the PSA 
has rapidly rising kinetics (e.g., PSAdt <6 months). The current 
study presents two cases of pathological 68Ga-PSMA uptake 
on PET/CT scans with PSA levels <2 ng/ml and slow PSA 
kinetics. These data, along with a number of cases identified in 
the published literature (Table I, data captured from a search of 
1,858 references in an ongoing systematic review with a cutoff 
date of August 2016), indicated that 68Ga-PSMA PET/CT may 
be a valuable imaging technique to localize disease in very 
early biochemical recurrence.
68Ga‑PSMA PET/CT identified pathological uptake in the 
bones in the first patient and in both the lymph nodes and the 
bones in the other patient. One of the current cases, as well 
as a number of cases presented in Table I, were identified to 
have a solitary site relapse in the bone. From a clinical point 
of view, the majority of published cases have a minimum 
amount of clinical and laboratory data to indicate if relapse 
was expected to occur at the prostate level, in lymph nodes 
or in the bones. The missing information includes data about 
resection margins, the nodal status at staging and/or surgery, 
and the levels and duration of post-treatment PSA levels 
(or time since curative treatment).
The presented data with 68Ga-PSMA PET/CT use in early 
recurrence are encouraging. Similar data with other PET 
tracers are scarce in the published literature. In several previous 
studies with choline PET/CT, no bone lesions were detected 
in early biochemical recurrence (10,11). Kjolhede et al (8) 
presented 5 patients with suspected bone lesions among 
58 patients with biochemical recurrence and PSA levels of 
<2 ng/ml, but there were no data on PSA kinetics in patients 
with bone lesions. Castellucci et al (9) performed 11C-choline 
PET/CT in 605 patients with biochemical recurrence and 
PSA levels of 0.2-2.0 ng/ml and a median PSAdt of 6 months, 
and showed pathological bone uptake in 51/172 patients with 
choline‑positive scans. The PSAdts of these 51 patients were 
not reported. It is appropriate to say that lesions detected by 
choline PET/CT must be cautiously interpreted due to low to 
moderate specificity; a study with verification by histology 
showed a low predictive value of 24% at the node level (19).
A number of trials are emerging that directly compare 
68Ga-PSMA with other PET tracers and standard imaging in 
MOLECULAR AND CLINICAL ONCOLOGY  6:  67-72,  2017 69
patients with biochemical recurrence. Although 68Ga-PSMA 
PET/CT appeared to detect more lesions than choline PET/CT, 
both on the whole patient level and at the level of individual 
lesions, the majority of studies include patients with high PSA 
levels, and there are limited data on skeletal involvement and 
characteristics of individual patients (20-22).
68Ga-PSMA PET/CT is developing rapidly (16,17). 
However, most studies are retrospective reports with inherent 
methodological deficiencies, including lack of compliance with 
the standards for reporting of diagnostic accuracy (STARD) 
criteria (23). One key feature of the STARD guidelines is the 
definition of the reference test. In the absence of a true reference, 
it remains unknown if PET uptake parallels tumor recurrence. 
This is well known with choline PET/CT (19), and it is shown with 
suspicious lesions without sclerosis on CT with NaF PET as in the 
current case no. 1. In the present cases, skeletal malignancy was 
Figure 2. Imaging of bone metastasis in a patient with prostate cancer with biochemical recurrence. A single bone metastasis was identified in the upper part 
of the fourth lumbar vertebra indicated by the arrow in all the images. The lesion was identified by 68Ga-PSMA-11 PET/CT as shown in (A) the sagittal view 
of the 68Ga-PSMA-11 PET image with (B) the corresponding fused 68Ga-PSMA-11 PET/CT and (C) by 18F-NaF-PET with (D) corresponding fused images of 
NaF PET/CT. Morphological changes were recognized as (E) discrete sclerotic changes on the low-dose CT and (F) by magnetic resonance imaging exhibiting 
a high signal on the sagittal short TI‑inversion recover image. PSMA, prostate specific membrane antigen; PET, positron emission tomography.
Figure 1. Prostate cancer imaging of biochemical recurrence. (A) MIP of the 68Ga-PSMA-11 PET image in the anterior view. The small, full arrows indicate 
pathologic PSMA uptake in the ribs (right 5th rib and left 3rd rib). The dotted arrow indicates a lesion in the left scapula, and the hatched arrow indicates uptake 
in the right scapula. (B) MIP of 18F‑NaF‑PET/CT confirmed the PSMA bone lesions shown in (A) and showed additional lesions in the ribs, the left scapula) and 
the right scapula (all full arrows). Axial 68Ga-PSMA PET image of the thorax shows pathologic PSMA-uptake in the left scapula (C) (indicated by the arrow), 
confirmed by 18F-NaF PET (D) and by mixed osteosclerotic and osteolytic lesions on low dose CT (E) (arrow). MIP, maximum-intensity projection; PSMA, 
prostate specific membrane antigen; PET, positron emission tomography.
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confirmed in both the patients with positive findings with two 
functional methods (68Ga-PSMA and NaF PET) and at least 
one anatomical method (low-dose CT and/or MRI). In addition, 
both patients responded biochemically to anti-cancer treatment.
In conclusion, 68Ga-PSMA PET/CT has emerged as a very 
promising imaging technique for use in identifying tumor sites 
in patients with biochemical recurrence. In comparison with 
standard imaging modalities as well as existing PET tracers, 
68Ga-PSMA PET/CT appeared to be sensitive at very low 
PSA levels (and in patients with slow PSA kinetics), which is 
optimal in terms of salvage radiotherapy.
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